MDS Hub maintains its focus on raising the levels of global knowledge of myelodysplastic syndromes in 2021

Press Release: Available for Immediate Release

The MDS Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), has continued to promote significant developments in the treatment and research of myelodysplastic syndromes (MDS) throughout Quarter 3 of 2021.

The MDS Hub provides news on the latest medical advancements relating to MDS, including updates on ongoing clinical trials and materials regarding cutting-edge discoveries in treatments and therapeutic regimens.

Reviewing the MDS Hub’s activity, Mia Hill, IME Director at Scientific Education Support, said:

“In September, the MDS Hub provided live coverage of the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021). We provided extensive coverage of the event through our social media channels, resulting in over 6,500 impressions and over 100 direct website visits. Most sessions were focused on current combination therapies, new approaches for lower-risk MDS, and future prospects for the management of MDS.

September was a busy month for the MDS Hub as we also covered the 16th International Congress on Myelodysplastic Syndromes, providing articles and interviews with key opinion leaders on the latest material from this meeting. Finally, we rounded off Quarter 3 with interview coverage of the International Academy for Clinical Hematology (IACH).”

We would like to take this opportunity to show our gratitude for our existing supporters—Novartis (Silver), Bristol Myers Squibb (Bronze), Geron Corporation (Contributor), and Takeda (Contributor).

For more information on the MDS Hub, please visit mds-hub.com.

For media enquiries, or to explore collaboration opportunities, please contact or syndromes (MDS) refer to a group of hematopoietic disorders that result in the production of insufficient numbers of healthy blood cells, along with changes in bone marrow morphology and, eventually, overall failure of the bone marrow. Progression of MDS can be indolent or aggressive, and some patients may go on to develop acute myeloid leukemia.

The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MDS. Our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The MDS Hub enables time-stretched HCPs to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, the MDS Hub supports HCPs worldwide.

The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

Funding for our hubs is made possible through financial support from the pharmaceutical industry. ​All content is developed by SES in collaboration with an expert steering committee. ​All content is independent, and the educational supporters are allowed no influence on the content.​

If you are interested in becoming an MDS supporter, please contact is a medical education company with projects such as community physician education though our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, including the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, Multiple Myeloma Hub, and MPN Hub.

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SMEs across Europe to form a network promoting cooperative research for curing leukemia.